Cargando…

GLP-1 Receptor Agonist NLY01 Reduces Retinal Inflammation and Neuron Death Secondary to Ocular Hypertension

Glaucoma is the leading cause of irreversible blindness and is characterized by the death of retinal ganglion cells (RGCs). Recent studies have implicated pro-inflammatory microglia, macrophages, and A1 astrocytes in the pathogenesis of neurodegenerative diseases. The role of pro-inflammatory, neuro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sterling, Jacob K., Adetunji, Modupe O., Guttha, Samyuktha, Bargoud, Albert R., Uyhazi, Katherine E., Ross, Ahmara G., Dunaief, Joshua L., Cui, Qi N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660987/ https://www.ncbi.nlm.nih.gov/pubmed/33147455 http://dx.doi.org/10.1016/j.celrep.2020.108271

Ejemplares similares

The GLP‐1/GIP dual‐receptor agonist DA5‐CH inhibits the NF‐κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP‐1 single‐receptor agonist NLY01
por: Lv, MiaoJun, et al.
Publicado: (2021)

AmericasNLI: Machine translation and natural language inference systems for Indigenous languages of the Americas
por: Kann, Katharina, et al.
Publicado: (2022)

Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma
por: Lawrence, Emily C. N., et al.
Publicado: (2023)

Inflammatory adipose activates a nutritional immunity pathway leading to retinal dysfunction
por: Sterling, Jacob K., et al.
Publicado: (2022)

Reversible Hydrogen Storage Media by g-CN Monolayer Decorated with NLi(4): A First-Principles Study
por: Chen, Xihao, et al.
Publicado: (2023)

Interleukin-6 triggers toxic neuronal iron sequestration in response to pathological α-synuclein
por: Sterling, Jacob K., et al.
Publicado: (2022)

The Co-factor of LIM Domains (CLIM/LDB/NLI) Maintains Basal Mammary Epithelial Stem Cells and Promotes Breast Tumorigenesis
por: Salmans, Michael L., et al.
Publicado: (2014)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Myeloid cell modulation by a GLP-1 receptor agonist regulates retinal angiogenesis in ischemic retinopathy
por: Zhou, Lingli, et al.
Publicado: (2021)

Practical and economic lithiations of functionalized arenes and heteroarenes using Cy(2)NLi in the presence of Mg, Zn or La halides in a continuous flow
por: Becker, Matthias R., et al.
Publicado: (2015)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

Clinical Trial Highlights – GLP-1 agonists
por: McFarthing, Kevin, et al.
Publicado: (2020)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
por: Madsen, Mette Simone Aae, et al.
Publicado: (2019)

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

Retinal Astrocytes and GABAergic Wide-Field Amacrine Cells Express PDGFRα: Connection to Retinal Ganglion Cell Neuroprotection by PDGF-AA
por: Takahama, Shokichi, et al.
Publicado: (2017)

Basal Insulin Use With GLP-1 Receptor Agonists
por: Anderson, Sarah L., et al.
Publicado: (2016)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

Novel severe oculocutaneous manifestations of human monkeypox virus infection and their historical analogues
por: Carrubba, Steven, et al.
Publicado: (2023)

Conditional Müller Cell Ablation Leads to Retinal Iron Accumulation
por: Baumann, Bailey, et al.
Publicado: (2017)

Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
por: Trapp, Stefan, et al.
Publicado: (2021)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
por: Whitley, Heather P., et al.
Publicado: (2023)

GLP-1 Receptor Agonist Effects on Normal and Neoplastic Pancreata
por: Goggins, Michael
Publicado: (2012)

Role and development of GLP-1 receptor agonists in the management of diabetes
por: Chia, Chee W, et al.
Publicado: (2009)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff, Lisa M, et al.
Publicado: (2010)

Targeting GLP-1 receptor trafficking to improve agonist efficacy
por: Jones, Ben, et al.
Publicado: (2018)

GLP-1 receptor agonist ameliorates experimental lung fibrosis
por: Fandiño, Juan, et al.
Publicado: (2020)

An overview of GLP-1 agonists and recent cardiovascular outcomes trials
por: Sheahan, Kelsey H, et al.
Publicado: (2020)

Medullary Carcinoma of Thyroid Due to GLP-1 Receptor Agonist
por: Vemula, Hasitha, et al.
Publicado: (2021)

GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight
por: Monti, Giulia, et al.
Publicado: (2022)

GLP-1 receptor agonist as a modulator of innate immunity
por: Chen, Jun, et al.
Publicado: (2022)

Effects of GLP-1 receptor agonists on neurological complications of diabetes
por: García-Casares, Natalia, et al.
Publicado: (2023)

Retinal iron homeostasis in health and disease
por: Song, Delu, et al.
Publicado: (2013)

A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor
por: Al-Zamel, Noura, et al.
Publicado: (2019)

Potential Treatment of Retinal Diseases with Iron Chelators
por: Shu, Wanting, et al.
Publicado: (2018)

Novel agonist and antagonist radioligands for the GLP‐2 receptor. Useful tools for studies of basic GLP‐2 receptor pharmacology
por: Gadgaard, Sarina, et al.
Publicado: (2022)

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
por: Lee, Jinmi, et al.
Publicado: (2012)

Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
por: Miñambres, Inka, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_aaf5ag5ffs96p0iijn3shqmcgd